These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28161826)

  • 41. Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map.
    Rosenkrantz AB; Kong X; Niver BE; Berkman DS; Melamed J; Babb JS; Taneja SS
    AJR Am J Roentgenol; 2011 Jan; 196(1):123-9. PubMed ID: 21178056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apparent Diffusion Coefficient Values of Prostate Cancer: Comparison of 2D and 3D ROIs.
    Tamada T; Huang C; Ream JM; Taffel M; Taneja SS; Rosenkrantz AB
    AJR Am J Roentgenol; 2018 Jan; 210(1):113-117. PubMed ID: 29045185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection.
    Rosenkrantz AB; Hindman N; Lim RP; Das K; Babb JS; Mussi TC; Taneja SS
    J Magn Reson Imaging; 2013 Sep; 38(3):694-700. PubMed ID: 23371846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
    Lim C; Flood TA; Hakim SW; Shabana WM; Quon JS; El-Khodary M; Thornhill RE; El Hallani S; Schieda N
    J Magn Reson Imaging; 2016 Mar; 43(3):726-36. PubMed ID: 26303719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.
    Glazer DI; Hassanzadeh E; Fedorov A; Olubiyi OI; Goldberger SS; Penzkofer T; Flood TA; Masry P; Mulkern RV; Hirsch MS; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2017 Mar; 42(3):918-925. PubMed ID: 27770164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A Hypothesis-generating Study.
    Hectors SJ; Semaan S; Song C; Lewis S; Haines GK; Tewari A; Rastinehad AR; Taouli B
    Radiology; 2018 Mar; 286(3):918-928. PubMed ID: 29117481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores.
    Wibmer A; Hricak H; Gondo T; Matsumoto K; Veeraraghavan H; Fehr D; Zheng J; Goldman D; Moskowitz C; Fine SW; Reuter VE; Eastham J; Sala E; Vargas HA
    Eur Radiol; 2015 Oct; 25(10):2840-50. PubMed ID: 25991476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer.
    Lawrence EM; Gallagher FA; Barrett T; Warren AY; Priest AN; Goldman DA; Sala E; Gnanapragasam VJ
    AJR Am J Roentgenol; 2014 Sep; 203(3):W280-6. PubMed ID: 25148185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apparent diffusion coefficient for prostate cancer imaging: impact of B values.
    Peng Y; Jiang Y; Antic T; Sethi I; Schmid-Tannwald C; Eggener S; Oto A
    AJR Am J Roentgenol; 2014 Mar; 202(3):W247-53. PubMed ID: 24555621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between Gleason score and apparent diffusion coefficient obtained from diffusion-weighted imaging of prostate cancer patients.
    Caivano R; Rabasco P; Lotumolo A; Cirillo P; D'Antuono F; Zandolino A; Villonio A; Macarini L; Salvatore M; Cammarota A
    Cancer Invest; 2013 Nov; 31(9):625-9. PubMed ID: 24138289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
    Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
    AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer?
    Faletti R; Battisti G; Discalzi A; Grognardi ML; Martinello S; Oderda M; Gontero P; Bergamasco L; Cassinis MC; Fonio P
    Abdom Radiol (NY); 2016 May; 41(5):926-33. PubMed ID: 27193791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.
    Renard Penna R; Cancel-Tassin G; Comperat E; Mozer P; Léon P; Varinot J; Roupret M; Bitker MO; Lucidarme O; Cussenot O
    World J Urol; 2016 Oct; 34(10):1389-95. PubMed ID: 26902878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer.
    Wu X; Reinikainen P; Vanhanen A; Kapanen M; Vierikko T; Ryymin P; Hyödynmaa S; Kellokumpu-Lehtinen PL
    Diagn Interv Imaging; 2017 Jan; 98(1):63-71. PubMed ID: 27687831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
    Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
    Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology.
    Boesen L; Chabanova E; Løgager V; Balslev I; Thomsen HS
    J Magn Reson Imaging; 2015 Aug; 42(2):446-53. PubMed ID: 25408104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results.
    Kim CK; Park BK; Lee HM; Kwon GY
    Invest Radiol; 2007 Dec; 42(12):842-7. PubMed ID: 18007156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?
    Itou Y; Nakanishi K; Narumi Y; Nishizawa Y; Tsukuma H
    J Magn Reson Imaging; 2011 Jan; 33(1):167-72. PubMed ID: 21182135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis.
    Shaish H; Kang SK; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Jan; 42(1):260-270. PubMed ID: 27562768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.
    Woodfield CA; Tung GA; Grand DJ; Pezzullo JA; Machan JT; Renzulli JF
    AJR Am J Roentgenol; 2010 Apr; 194(4):W316-22. PubMed ID: 20308476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.